TITLE

Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer

AUTHOR(S)
Uzunoglu, Sernaz; Aybatlı, Aysun; Kaplan, Petek; Cicin, Irfan; Sut, Necdet; Sayın, Cenk; Varol, Fusun
PUB. DATE
March 2013
SOURCE
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The goal of this study was to evaluate the efficacy of CA-125 area under the curve (CA-125 AUC) as a prognostic factor following surgical treatment for ovarian cancer patients. A retrospective analysis was conducted on ninety-five patients with ovarian cancer who had primary treatment in a tertiary center between 2000 and 2010. After either optimal or cytoreductive surgery, all patients underwent adjuvant chemotherapy. CA-125 AUC was calculated for each patient that had a minimum of three CA-125 serum measurements during the treatment period. The mean age at diagnosis and mean survival were 53.9 years (range, 16-75 years) and 35.6 ± 22.9 months (range, 3.1-95.4 months), respectively. The mean (and median) CA-125 AUC of patients of FIGO stages I, II, III, and IV was 53.0 (42.5), 58.06 (58.06), 97.8 (54.6), and 405.2 (149.3) IU/ml day, respectively ( p = 0.004). The mean CA-125 AUC was 57.7, 410.1, and 636.3 IU/ml day for patients with a complete response, partial response, and no response/progressive disease to first-line chemotherapy, respectively ( p < 0.001). The CA-125 AUC cut-off level for an overall survival of ≥5 years was 99.75 IU/ml day with a sensitivity of 90.9 % (95 % CI, 70.8-98.6) with 1.27 as positive likelihood ratio. Patients who suffer from ovarian cancer, with a lower CA125 AUC, have a better overall survival than those with a higher CA125 AUC. CA-125 AUC could be used as an independent factor for evaluating the treatment efficacy and chemotherapy response.
ACCESSION #
85859768

 

Related Articles

  • Adjuvant chemotherapy for stage II colon cancer: who really needs it. Yang, Yan; Yang, Yang; Yang, Hui; Wang, Fen; Wang, Huihui; Chen, Qi; Liu, Ying; Li, Aiying; Zhang, Quanan // Cancer Management & Research;Aug2018, Vol. 10, p2509 

    Background: Although there is evidence that failure to reach the baseline of 12–13 lymph nodes in resected specimens is related to poor prognosis of patients with stage II colon cancer, and may be a marker of adjuvant therapy, the use of these markers remains controversial. The objective...

  • Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. Wang, Ying; Liu, Ping; Xu, Yan; Zhang, Weihao; Tong, Lina; Guo, Zhi; Ni, Hong // Cancer Chemotherapy & Pharmacology;Feb2015, Vol. 75 Issue 2, p255 

    Purpose: To investigate the role of preoperative neutrophil-to-lymphocyte ratio (NLR) in prediction of response to first-line platinum-based chemotherapy and survival outcome in serous ovarian cancer (SOC) patients. Methods: Clinicopathologic data were reviewed for patients with SOC treated with...

  • Clinical features of long-term survivors of recurrent epithelial ovarian cancer. Iwase, Haruko; Takada, Toshio; Iitsuka, Chiaki; Nomura, Hidetaka; Abe, Akiko; Taniguchi, Tomoko; Sakamoto, Kimihiko; Takizawa, Ken; Takeshima, Nobuhiro // International Journal of Clinical Oncology;Feb2015, Vol. 20 Issue 1, p143 

    Background: Although recurrent epithelial ovarian cancer (EOC) is generally regarded as an incurable disease, some patients survive more than 5 years after the first recurrence. The aim of this study was to evaluate the clinical features of patients with recurrent EOC who achieve long-term...

  • Pursuing the NED condition in stage IV colorectal cancer.  // Annals of Oncology;Sep2012 Supplement 9, Vol. 23 Issue suppl_9, pix35 

    No abstract available.

  • Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents. Bamias, aristotle; Bamia, Christine; Zagouri, Flora; Kostouros, Efthimios; Kakoyianni, Konstantina; Rodolakis, alexandros; Vlahos, George; Haidopoulos, Dimitrios; Thomakos, Nikolaos; antsaklis, aris; Dimopoulos, Meletios-athanasios // Oncology;Jan2013, Vol. 84 Issue 3, p158 

    Objective: The prognosis for patients with platinum-resistant advanced ovarian cancer remains poor. The impact of approved agents on survival has not been clarified during the last decade. We studied survival trends during the last 15 years in platinum-resistant patients treated with...

  • A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer. Yildiz, Ibrahim; Tas, Faruk; Kilic, Leyla; Sen, Fatma; Saip, Pinar; Eralp, Yesim; Keskin, Serkan; Karabulut, Senem; Ciftci, Rumeysa; Serilmez, Murat; Yasasever, Vildan; Aydiner, Adnan // Cancer Chemotherapy & Pharmacology;Aug2013, Vol. 72 Issue 2, p437 

    Purpose: This study was conducted to determine the clinical significance of serum M30 and M65 in epithelial ovarian cancer (EOC). Methods: A total of 56 patients with EOC and 56 healthy women were included in the study. All of the patients received platinum-based chemotherapy. Pretreatment...

  • Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. Tone, Alicia A.; McConechy, Melissa K.; Yang, Winnie; Jiarui Ding; Yip, Stephen; Kong, Esther; Kwong-Kwok Wong; Gershenson, David M.; Mackay, Helen; Shah, Sohrab; Gilks, Blake; Tinker, Anna V.; Clarke, Blaise; McAlpine, Jessica N.; Huntsman, David // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Ovarian low-grade serous carcinoma (LGSC) has fewer mutations than ovarian high-grade serous carcinoma (HGSC) and a less aggressive clinical course. However, an overwhelming majority of LGSC patients do not respond to conventional chemotherapy resulting in a poor long-term prognosis...

  • Cost of advanced ovarian cancer: PDS vs NACT.  // PharmacoEconomics & Outcomes News;Apr2015, Vol. 726 Issue 1, p13 

    The article offers information on a study conducted in the U.S. that compared the treatment costs of primary debulking surgery (PDS) and neo-adjuvant chemotherapy (NACT) used on women with ovarian cancer.

  • Erratum to: The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Crane, Lucia; Arts, Henriette; Oosten, Marleen; Low, Philip; Zee, Ate; Dam, Gooitzen; Bart, Joost // Cellular Oncology (2211-3428);Jun2012, Vol. 35 Issue 3, p229 

    A correction to the article "The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer" that was published in the June 2011 issue is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics